• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Dynavax Technologies Corporation

    8/6/24 5:01:38 PM ET
    $DVAX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $DVAX alert in real time by email
    S-8 1 dvax-20240806.htm S-8 S-8

     

    As filed with the Securities and Exchange Commission on August 6, 2024

    Registration No. 333-

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER THE SECURITIES ACT OF 1933

     

     

    DYNAVAX TECHNOLOGIES CORPORATION

    (Exact Name of Registrant as Specified in its Charter)

     

     

    Delaware
    (State or other jurisdiction of incorporation or organization)

     

    33-0728374

    (I.R.S. Employer Identification No.)

     

    2100 Powell Street, Suite 720

    Emeryville, CA 94608

    (510) 848-5100

    (Address, Including Zip Code, and Telephone Number,

    Including Area Code, of Registrant’s Principal Executive Offices)

     

     

    Dynavax Technologies Corporation 2018 Equity Incentive Plan

    (Full Title of the Plan)

     

    Ryan Spencer

    Chief Executive Officer

    Dynavax Technologies Corporation

    2100 Powell Street, Suite 720

    Emeryville, CA 94608

    (510) 848-5100

    (Name, Address, Including Zip Code, and Telephone Number,

    Including Area Code, of Agent for Service)

     

     

    Copies to:

     

    Steven M. Przesmicki, Esq.

    Cooley LLP

    10265 Science Center Drive

    San Diego, CA 92121

    (858) 550-6000

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

    Large accelerated filer 

     

     

    Accelerated filer 

    Non-accelerated filer 

     

    Smaller reporting company 

    Emerging growth company 

     

     

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. 

     

     

    1


     

    PART I

     

    EXPLANATORY NOTE AND GENERAL INSTRUCTION E INFORMATION

     

    This Registration Statement on Form S-8 is being filed by Dynavax Technologies Corporation (“Dynavax” or the “Company”) for the purpose of registering an additional 11,400,000 shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), issuable under the Company’s 2018 Equity Incentive Plan (the “2018 EIP”). The shares of the Company’s Common Stock previously reserved for issuance under the 2018 EIP were registered on the Registrant’s Registration Statements on Form S-8 (File Nos. 333-225525, 333-233247, 333-241674, and 333-265373) filed with the Securities and Exchange Commission (the “Commission”) on June 8, 2018, August 13, 2019, August 6, 2020, and June 2, 2022 (the “Prior Forms S-8”). This Registration Statement relates to securities of the same class as those to which the Prior Forms S-8 relate and is submitted in accordance with General Instruction E of Form S-8. Pursuant to General Instruction E of Form S-8, the contents of Prior Forms S-8 are incorporated by reference herein.

     

    PART II


    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
     

    Item 3.

    Incorporation of Documents by Reference

    The following documents filed by the Registrant with the Commission are incorporated by reference into this Registration Statement:

    ●

    the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2023, filed with the Commission on February 22, 2024;

     

     

    ●

    the Registrant’s Quarterly Reports on Form 10-Q for the quarterly period ended March 31, 2024 and June 30, 2024, filed with the Commission on May 8, 2024 and August 6, 2024;

     

     

    ●

    the Registrant’s Current Reports on Form 8-K, filed with the Commission on March 12, 2024, April 1, 2024, May 24, 2024 and August 2, 2024;

     

     

    ●

    the information specifically incorporated by reference into the Registrant’s Annual Report on Form 10-K referred to above from the Registrant’s definitive proxy statement relating to the Registrant’s 2024 annual meeting of stockholders, filed with the Commission on April 11, 2024, including the Registrant’s definitive additional materials relating to the Registrant’s 2024 annual meeting of stockholders, filed with the Commission on April 26, 2024; and

     

     

    ●

    the description of the Registrant’s common stock set forth in the Registrant’s registration statement on Form 8-A, filed with the Commission on February 6, 2004, including any amendments or reports filed for purpose of updating such description, including Exhibit 4.1 of the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2023, filed with the Commission on February 22, 2024.

    All reports and other documents filed by the Registrant pursuant to Section 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), other than Current Reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits furnished on such form that relate to such items, after the date of this Registration Statement and prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part of this Registration Statement from the date of filing such reports and documents. Any statement contained in a document incorporated or deemed to be incorporated herein by reference shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes that statement. Any such statement so modified or superseded shall not constitute a part of this Registration Statement, except as so modified or superseded.

     

     

    2


     

     

    Item 8.

    Exhibits

     

     

     

    Incorporation by Reference

    Exhibit

     

    Exhibit

     

     

     

    Number

    Description

    Number

    Filing

    Filing Date

    File No.

    4.1

    Sixth Amended and Restated Certificate of Incorporation.

    3.1

    S-1/A

    February 5, 2004

    333-109965

    4.2

    Certificate of Amendment of Amended and Restated Certificate of Incorporation.

    3.1

    8-K

    January 4, 2010

    001-34207

    4.3

    Certificate of Amendment of Amended and Restated Certificate of Incorporation.

    3.1

    8-K

    January 5, 2011

    001-34207

    4.4

    Certificate of Amendment of Amended and Restated Certificate of Incorporation.

    3.6

    8-K

    May 30, 2013

    001-34207

    4.5

    Certificate of Amendment of the Sixth Amended and Restated Certificate of Incorporation.

    3.1

    8-K

    November 10, 2014

    001-34207

    4.6

    Certificate of Amendment of the Sixth Amended and Restated Certificate of Incorporation.

    3.1

    8-K

    June 2, 2017

    001-34207

    4.7

    Certificate of Amendment of the Sixth Amended and Restated Certificate of Incorporation.

    3.1

    8-K

    July 31, 2017

    001-34207

    4.8

    Certificate of Amendment of the Sixth Amended and Restated Certificate of Incorporation.

    3.1

    8-K

    May 29, 2020

    001-34207

    4.9

    Amended and Restated Bylaws.

    3.8

    10-Q

    November 6, 2018

    001-34207

    4.10

    Form of Specimen Common Stock Certificate.

    4.2

    S-1/A

    January 16, 2004

    333-109965

    4.11

    Indenture between Company and U.S. Bank National Association as trustee, dated May 13, 2021.

    4.1

    8-K

    May 13, 2021

    001-34207

    4.12

    Form of Global Note, representing Dynavax Technologies Corporation’s 2.50% Convertible Senior Notes Due 2026.

    4.1

    8-K

    May 13, 2021

    001-34207

    5.1*

    Opinion of Cooley LLP.

    23.1*

    Consent of Independent Registered Public Accounting Firm.

     

     

     

     

    23.2*

    Consent of Cooley LLP (included in Exhibit 5.1).

     

     

     

     

    24.1*

    Power of Attorney (included on the signature page to this Registration Statement).

     

     

     

     

    99.1

    Dynavax Technologies Corporation 2018 Equity Incentive Plan.

    10.1

    10-Q

    August 6, 2024

    001-34207

    107*

    Filing Fee Table.

     

    * Filed herewith

     

     

    3


     

    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Emeryville, State of California, on this 6th day of August, 2024.

     

     

     

    DYNAVAX TECHNOLOGIES CORPORATION

     

     

     

     

     

     

    By:

    /s/ RYAN SPENCER

     

    Ryan Spencer

     

    Chief Executive Officer and Director

     

    (Principal Executive Officer)

     

     

    4


     

    POWER OF ATTORNEY

    KNOW ALL PERSONS BY THESE PRESENT, that each person whose signature appears below does hereby constitute and appoint Ryan Spencer and Kelly MacDonald, and each of them, with full power of substitution and full power to act without the other, his or her true and lawful attorney-in-fact and agent to act for him or her and in their name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file this Registration Statement, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in order to effectuate the same as fully, to all intents and purposes, as they or he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

     

     

    Signature

     

    Title

     

    Date

     

     

     

     

     

     

    /s/ RYAN SPENCER

     

    Chief Executive Officer

     

    August 6, 2024

    Ryan Spencer

     

    (Principal Executive Officer)

     

     

     

     

     

     

     

     

     

     

     

     

    /s/ KELLY MACDONALD

     

    Chief Financial Officer

     

    August 6, 2024

    Kelly MacDonald

     

    (Principal Financial Officer)

     

     

     

     

     

     

     

     

     

     

     

     

    /s/ JUSTIN BURGESS

     

    Chief Accounting Officer

     

    August 6, 2024

    Justin Burgess

     

    (Principal Accounting Officer)

     

     

     

     

     

     

     

     

     

     

     

     

    /s/ SCOTT MYERS

     

     

     

    August 6, 2024

    Scott Myers

     

    Chairman of the Board

     

     

     

     

     

     

     

     

     

     

     

     

    /s/ FRANCIS R. CANO

     

     

     

    August 6, 2024

    Francis R. Cano, Ph.D.

     

    Director

     

     

     

     

     

     

     

     

     

     

     

     

    /s/ JULIE EASTLAND

     

     

     

    August 6, 2024

    Julie Eastland

     

    Director

     

     

     

     

     

     

     

     

     

     

     

     

    /s/ DANIEL L. KISNER

     

     

     

    August 6, 2024

    Daniel L. Kisner, M.D.

     

    Director

     

     

     

     

     

     

     

     

     

     

     

     

    /s/ BRENT MACGREGOR

     

     

     

    August 6, 2024

    Brent MacGregor

     

    Director

     

     

     


     

    Signature

     

    Title

     

    Date

     

     

     

     

     

     

     

     

     

     

    /s/ PETER R. PARADISO

     

     

     

    August 6, 2024

    Peter R. Paradiso, Ph.D.

     

    Director

     

     

     

     

     

     

     

     

     

     

     

     

    /s/ PEGGY V. PHILLIPS

     

     

     

    August 6, 2024

    Peggy V. Phillips

     

    Director

     

     

     

     

     

     

     

     

     

     

     

     

    /s/ ELAINE D. SUN

     

     

     

    August 6, 2024

    Elaine D. Sun

     

    Director

     

     

     

     

     

     

     

     

     

     

     

     

     


    Get the next $DVAX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DVAX

    DatePrice TargetRatingAnalyst
    2/11/2025$15.00 → $12.00Neutral → Sell
    Goldman
    2/1/2024$20.00Neutral
    Goldman
    9/27/2022$22.00Mkt Outperform
    JMP Securities
    1/6/2022$38.00Buy
    Goldman
    12/29/2021$23.00 → $28.00Buy
    HC Wainwright & Co.
    8/31/2021$20.00 → $23.00Buy
    HC Wainwright & Co.
    8/6/2021$19.00Buy
    Goldman Sachs
    8/5/2021$16.00 → $20.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $DVAX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President & COO Novack David F exercised 114,000 shares at a strike of $9.83 and sold $1,782,960 worth of shares (114,000 units at $15.64) (SEC Form 4)

    4 - DYNAVAX TECHNOLOGIES CORP (0001029142) (Issuer)

    1/20/26 4:33:32 PM ET
    $DVAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SVP and CFO Macdonald Kelly covered exercise/tax liability with 36,141 shares, was granted 37,500 shares and converted options into 29,618 shares, increasing direct ownership by 106% to 60,204 units (SEC Form 4)

    4 - DYNAVAX TECHNOLOGIES CORP (0001029142) (Issuer)

    12/29/25 4:15:14 PM ET
    $DVAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    VP, Chief Accounting Officer Metzinger Joseph Anthony converted options into 12,727 shares and covered exercise/tax liability with 5,598 shares (SEC Form 4)

    4 - DYNAVAX TECHNOLOGIES CORP (0001029142) (Issuer)

    12/29/25 4:12:10 PM ET
    $DVAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DVAX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Myers Scott Dunseth bought $41,116 worth of shares (3,800 units at $10.82), increasing direct ownership by 12% to 35,004 units (SEC Form 4)

    4 - DYNAVAX TECHNOLOGIES CORP (0001029142) (Issuer)

    8/25/25 8:50:44 AM ET
    $DVAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DVAX
    SEC Filings

    View All

    Dynavax Technologies Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update

    8-K - DYNAVAX TECHNOLOGIES CORP (0001029142) (Filer)

    2/10/26 9:10:02 AM ET
    $DVAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 14D9/A filed by Dynavax Technologies Corporation

    SC 14D9/A - DYNAVAX TECHNOLOGIES CORP (0001029142) (Subject)

    2/10/26 6:36:19 AM ET
    $DVAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 14D9/A filed by Dynavax Technologies Corporation

    SC 14D9/A - DYNAVAX TECHNOLOGIES CORP (0001029142) (Subject)

    2/2/26 6:30:15 AM ET
    $DVAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DVAX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Ciena Set to Join S&P 500; Arrowhead Pharmaceuticals to Join S&P MidCap 400; ADT and OneSpaWorld Holdings to Join S&P SmallCap 600

    NEW YORK, Feb. 4, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400, S&P SmallCap 600:  S&P MidCap 400 constituent Ciena Corp. (NYSE:CIEN) will replace Dayforce Inc. (NYSE:DAY) in the S&P 500, S&P SmallCap 600 constituent Arrowhead Pharmaceuticals Inc. (NASD: ARWR) will replace Ciena in the S&P MidCap 400, and ADT Inc. (NYSE:ADT) will replace Arrowhead Pharmaceuticals in the S&P SmallCap 600 effective prior to the opening of trading on Monday, February 9. Thoma Bravo L.P. acquired Dayforce in a deal that closed today.OneSpaWorld Holdings Ltd. (NASD: OSW) will replace Dynavax Technologies Corp. (NASD: DVAX) in the S&P SmallCap 600 effec

    2/4/26 6:15:00 PM ET
    $ADT
    $ARWR
    $CIEN
    Diversified Commercial Services
    Consumer Discretionary
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sanofi to Acquire Dynavax, Adding a Marketed Adult Hepatitis B Vaccine and Phase 1/2 Shingles Candidate to the Pipeline

    Dynavax stockholders to receive $15.50 in cash, a 39% premium to Dynavax closing share price onDecember 23, 2025 EMERYVILLE, Calif., Dec. 24, 2025 /PRNewswire/ -- Sanofi announced today that it has entered into an agreement to acquire Dynavax Technologies Corporation (NASDAQ:DVAX), a publicly traded vaccines company with a marketed adult hepatitis B vaccine (HEPLISAV-B®) and a differentiated shingles vaccine candidate. The acquisition augments Sanofi's presence in adult immunization by bringing together Dynavax's vaccines with Sanofi's global scale, development capabilities and commercial reach.

    12/24/25 1:23:00 AM ET
    $DVAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dynavax to Participate at the 8th Annual Evercore Healthcare Conference

    EMERYVILLE, Calif., Nov. 19, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ:DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that the Company will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Tuesday, December 2nd at 2:10 p.m. ET. The presentations will be webcast and may be accessed through the "Events & Presentations" page on the "Investors" section of the Company's website at https://investors.dynavax.com/events-presentations. About DynavaxDynavax is a

    11/19/25 4:01:00 PM ET
    $DVAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DVAX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Dynavax downgraded by Goldman with a new price target

    Goldman downgraded Dynavax from Neutral to Sell and set a new price target of $12.00 from $15.00 previously

    2/11/25 7:05:05 AM ET
    $DVAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Goldman initiated coverage on Dynavax with a new price target

    Goldman initiated coverage of Dynavax with a rating of Neutral and set a new price target of $20.00

    2/1/24 6:20:13 AM ET
    $DVAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    JMP Securities initiated coverage on Dynavax with a new price target

    JMP Securities initiated coverage of Dynavax with a rating of Mkt Outperform and set a new price target of $22.00

    9/27/22 7:39:04 AM ET
    $DVAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DVAX
    Leadership Updates

    Live Leadership Updates

    View All

    Ciena Set to Join S&P 500; Arrowhead Pharmaceuticals to Join S&P MidCap 400; ADT and OneSpaWorld Holdings to Join S&P SmallCap 600

    NEW YORK, Feb. 4, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400, S&P SmallCap 600:  S&P MidCap 400 constituent Ciena Corp. (NYSE:CIEN) will replace Dayforce Inc. (NYSE:DAY) in the S&P 500, S&P SmallCap 600 constituent Arrowhead Pharmaceuticals Inc. (NASD: ARWR) will replace Ciena in the S&P MidCap 400, and ADT Inc. (NYSE:ADT) will replace Arrowhead Pharmaceuticals in the S&P SmallCap 600 effective prior to the opening of trading on Monday, February 9. Thoma Bravo L.P. acquired Dayforce in a deal that closed today.OneSpaWorld Holdings Ltd. (NASD: OSW) will replace Dynavax Technologies Corp. (NASD: DVAX) in the S&P SmallCap 600 effec

    2/4/26 6:15:00 PM ET
    $ADT
    $ARWR
    $CIEN
    Diversified Commercial Services
    Consumer Discretionary
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Deep Track Capital Comments on ISS Recommendation

    Strongly Disagrees with Recommendation and Believes ISS Ignored Key Issues in Its Incomplete Analysis ISS Has Chosen Not to Hold the Board Accountable for Its Underperformance in Recent Years, Heplisav's Waning Market Share Growth and Poor Corporate Governance Urges Shareholders to Vote FOR Deep Track's Four Highly Qualified Director Nominees Deep Track Capital, LP, (together with its affiliates, "Deep Track" or "we"), one of the largest shareholders of Dynavax Technologies Corporation (NASDAQ:DVAX) ("Dynavax", "DVAX" or the "Company"), with ownership of approximately 14.82% of the Company's outstanding shares, today issued the following statement in response to a report issued by Instit

    5/23/25 6:12:00 PM ET
    $DVAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Leading Independent Proxy Advisory Firm ISS Recommends Stockholders Vote "FOR" All Four of Dynavax's Highly Qualified Director Nominees

    ISS Recognizes There is No Case for Change Dynavax's Superior Strategy and Current Board are Best Equipped to Deliver Significant Long-Term Stockholder Value Dynavax Comments on Deep Track's Misleading Supplemental Materials Urges Stockholders to Follow ISS Recommendation and Vote "FOR" ALL Four of Dynavax's Highly Qualified Director Nominees on the GOLD Proxy Card Today EMERYVILLE, Calif., May 23, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ:DVAX) ("Dynavax" or the "Company"), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that leading independent proxy advisory firm, Institutional Shareholder Services ("ISS

    5/23/25 1:44:00 PM ET
    $DVAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DVAX
    Financials

    Live finance-specific insights

    View All

    Dynavax Reports Third Quarter 2025 Financial Results and Announces New $100 Million Share Repurchase Program

    HEPLISAV-B® quarterly net product revenue of $90 million, a 13% YoY increase; reiterates full year 2025 HEPLISAV-B® net product revenue guidance range of $315 to $325 millionBoard of Directors authorizes new $100 million share repurchase program Positive topline Phase 1/2 shingles vaccine trial data presented in late-breaker session at IDWeek Enters exclusive license agreement for Vaxart's novel oral COVID-19 vaccine program, expanding pipeline opportunitiesConference call today at 4:30 p.m. ET/1:30 p.m. PTEMERYVILLE, Calif., Nov. 5, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ:DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vacc

    11/5/25 4:01:00 PM ET
    $DVAX
    $VXRT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Dynavax to Report Third Quarter 2025 Financial Results and Host Conference Call on November 5, 2025

    EMERYVILLE, Calif., Oct. 22, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ:DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will report third quarter 2025 financial results on Wednesday, November 5, 2025, after the U.S. financial markets close. Dynavax will host a conference call and live audio webcast on Wednesday, November 5, 2025, at 4:30 p.m. ET/1:30 p.m. PT. The live audio webcast may be accessed through the "Events & Presentations" page on the "Investors" section of the Company's website at https://in

    10/22/25 4:01:00 PM ET
    $DVAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dynavax Reports Second Quarter 2025 Financial Results

    Record HEPLISAV-B® quarterly net product revenue of $92 million, representing 31% year-over-year growthRefines full year 2025 HEPLISAV-B net product revenue guidance range to $315 to $325 million, from $305 to $325 millionTop-line results in Part 1 of Phase 1/2 shingles vaccine trial expected in August 2025Completed dosing in Part 1 of Phase 1/2 trial of pandemic influenza adjuvant programConference call today at 4:30 p.m. ET/1:30 p.m. PTEMERYVILLE, Calif., Aug. 7, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ:DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today reported financial results and provided a business update

    8/7/25 4:00:00 PM ET
    $DVAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DVAX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Dynavax Technologies Corporation

    SC 13G - DYNAVAX TECHNOLOGIES CORP (0001029142) (Subject)

    11/14/24 12:18:08 PM ET
    $DVAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Dynavax Technologies Corporation

    SC 13D/A - DYNAVAX TECHNOLOGIES CORP (0001029142) (Subject)

    10/24/24 4:06:57 PM ET
    $DVAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Dynavax Technologies Corporation

    SC 13G/A - DYNAVAX TECHNOLOGIES CORP (0001029142) (Subject)

    10/16/24 9:37:13 AM ET
    $DVAX
    Biotechnology: Pharmaceutical Preparations
    Health Care